Teva Pharmaceutical Industries Ltd. - Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results · July 7, 2026 · 2 pages
Preview this press release
Create a free account to start reading
Full documents are included with Professional
Earnings release
32 pages
Jul 29, 2026
Quarterly report
127 pages
Jul 29, 2026
Presentation
Teva Pharmaceutical Industries Limited - Q2 2026 - Slides
74 pages
Presentation
19 pages
Presentation
23 pages
Press release
Teva Pharmaceutical Industries Ltd. - Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
2 pages
Jul 7, 2026
Press release
Teva Pharmaceutical Industries Ltd. - Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
3 pages
Already premium?